CASI Pharmaceuticals annual free cash flow
2020
2021
2022
2023
2024
2025
CASI Pharmaceuticals Free Cash Flow (FCF) History (CASIF)
CASI Pharmaceuticals reported −$20.8M in free cash flow for fiscal 2025, an increase of $8.7M from the previous fiscal year, with a free cash flow margin of −100.28%.
View full CASI Pharmaceuticals company overviewCASI Pharmaceuticals free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$20.8M | $8.7M | — | −100.28% |
| 2024 | 2024-12-31 | −$29.4M | −$9.3M | — | −103.19% |
| 2023 | 2023-12-31 | −$20.2M | $6.5M | — | −59.54% |
| 2022 | 2022-12-31 | −$26.7M | $9.1M | — | −70.18% |
| 2021 | 2021-12-31 | −$35.8M | −$8.4M | — | −119.21% |
| 2020 | 2020-12-31 | −$27.4M | — | — | −182.55% |
CASI Pharmaceuticals quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
CASI Pharmaceuticals free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$27.4M to −$20.8M, a net increase of $6.6M.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review CASI Pharmaceuticals filings at SEC.gov ↗